Neoplasms

All Conditions

Rare Diseases

Glioma

Neoplasms, Neuroepithelial

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neuroepithelioma

Antineoplastic Agents

All Drugs and Chemicals

TIC10 compound

ONC201 (dordaviprone) is a ClpP agonist and DRD2 antagonist.

ONC201 (dordaviprone)

Rohinton Tarapore, PhD

Madelyn Cooper

Ramya Tadipatri, MD

Hema V Buddha

Richard M Green, MD

Mariko Sato

Megan Paul, MD

Akanksha Sharma, MD

Ashley Mettetal

Kathleen Dorris, MD

Lindsay Kilburn, MD, MS

Yazmin Odia, MD, MS

Anais Vega

Nikki Pope

Petros Nikolinakos, MD

Andrea Siu, MPH

Kelley Hutchins, DO

Angela Waanders, MD, MPH

David Dickens, MD

Misty Gravelin

Carl Koschmann, MD, MS

Clark Chen, MD, PhD

Andrew Cluster, MD

Alison Barnwell

Nicole Shonka

Robert Aiken, MD

Lauren Weintraub, MD

Anna Yaffe

Sharon Gardner, MD

David Korones, MD

Jennifer Serventi, PA

Sara Guedry

Prakash Ambady

Alison Patterson

Daniel Bowers, MD

Teresa Hannah

Nazanin Majd

Wafik Zaky

Yuri Kida

Joe Mendez

Melissa Mark, MD

This is an intermediate-size expanded access protocol to provide ONC201 (dordaviprone) to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 (dordaviprone) through clinical trials.

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Chimerix

Spots Global Cancer Trial Database for onc201 (dordaviprone)